Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No label control group Clear all
Completed Phase 1 Interventional

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions
JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Cognitive Behavioral Therapy - Insomnia (CBT-I) Among Professional Firefighters

NCT05087121
View directory record Official record
Conditions
Insomnia, Shift-Work Related Sleep Disturbance
Interventions
Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F), Fitbit Inspire HR Wrist Worn Device (NCT04176926)
Behavioral · Device
Lead sponsor
Pacific University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Forest Grove, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 30, 2026, 5:08 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

NCT07076862
View directory record Official record
Conditions
PASC Post Acute Sequelae of COVID-19
Interventions
A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Sep 30, 2026, 5:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

NCT05630963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aversive stimuli, PET radiotracer
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Impact of Front-of-package Nutrient Labels

NCT06673706
View directory record Official record
Conditions
Nutrition Knowledge, Attitudes, Dietary Habits, Dietary Behavior
Interventions
Front-of-package label
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
10,601 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328
View directory record Official record
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Environmental Nudges on Dietary Quality

NCT06119165
View directory record Official record
Conditions
Healthy Diet
Interventions
Environmental nudges
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
2,132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

NCT02665221
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No Treatment Arm, Topical Preparation H arm
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

NCT00071097
View directory record Official record
Conditions
HIV Infections
Interventions
TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Not applicable Interventional

Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors

NCT02452710
View directory record Official record
Conditions
Fatigue in Cancer Survivors
Interventions
Placebo
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

NCT05371080
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Not applicable Interventional

Tolvaptan for Patients With Acute Neurological Injuries

NCT02545114
View directory record Official record
Conditions
Hyponatremia, SIADH
Interventions
Tolvaptan
Drug
Lead sponsor
Polderman, Kees, H., MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 30, 2026, 5:08 PM EDT
Completed No phase listed Observational

The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency

NCT04580693
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
PET Scan
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 30, 2026, 5:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069
View directory record Official record
Conditions
Glioblastoma Multiforme, Adult
Interventions
Berubicin, Lomustine
Drug
Lead sponsor
CNS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
32
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional

Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

NCT01868984
View directory record Official record
Conditions
Fistula Stenosis
Interventions
Paclitaxel, Standard Therapy
Drug · Procedure
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Add on Lacosamide Versus High Dose Monotherapy

NCT01345058
View directory record Official record
Conditions
Epilepsy
Interventions
lacosamide, levetiracetam
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Phase 4 Interventional Results available

Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

NCT01194531
View directory record Official record
Conditions
Preimplantation Gentic Screening (PGS), In Vitro Fertilization (IVF), Preimplantation Genetic Diagnosis (PGD)
Interventions
24 Chromosome Aneuploidy Screening with Parental Support
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Laguna Hills, California • Washington D.C., District of Columbia • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Results available

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

NCT00266656
View directory record Official record
Conditions
Turner Syndrome
Interventions
Humatrope
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 20 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Sep 30, 2026, 5:08 PM EDT
Not listed No phase listed Observational

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

NCT06461468
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
American Heart Association
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Fairhope, Alabama • Kankakee, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Withdrawn No phase listed Observational

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

NCT04782297
View directory record Official record
Conditions
CKD, ESRD
Interventions
Long term hemodialysis catheter
Device
Lead sponsor
Medical Components, Inc dba MedComp
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yale Wellness Project

NCT03229577
View directory record Official record
Conditions
Mental Health Wellness 1
Interventions
Sudarshan Kriya Yoga, Mindfulness-Based Stress Reduction, Emotional Intelligence
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

NCT03784963
View directory record Official record
Conditions
Heart Failure, Gastrointestinal Bleeding
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 30, 2026, 5:08 PM EDT